Richard Y. Ebright, MD, PhD

Instructor in Gastrointestinal Oncology, @DanaFarber | combination treatments, functional genomics, RAS inhibition, therapeutic development

[Richard Y. Ebright, MD, PhD @RYEbright]

How should we be drugging RAS and developing clinical combinations for RAS-driven tumors?

@andrewaguirremd, Alice Shaw, @Julien__Dilly, and I have a lot of thoughts (>15,000 words of thoughts), and our mega review is out now at @CD_AACR! Check it out: https://t.co/sUU5fzpM7f

[Cancer Discovery @CD_AACR]

Online now for the #AACR25 session on Advances in #KRAS Biology in PDAC by session speaker @andrewaguirremd: Response and Resistance to RAS inhibition in Cancer https://t.co/y2lwO3oXdz

[Richard Y. Ebright, MD, PhD @RYEbright]

Honored to have had the opportunity to share our work at the @AACR Conference on Pancreatic Cancer! KRAS inhibitors are a huge advance, but combination therapies can enhance efficacy and prevent resistance. Lots of exciting progress to come! #AACRpan26

[AACR @AACR]

RAS Inhibition: Response, Resistance, and Rational Combinations—
Kenneth Olive, Arsen Osipov, Rosalie Sears, Richard Ebright, and Qingxiang Lin addressed this topic in a plenary at the AACR Conference on Pancreatic Cancer.
#AACRpan26 @DrArsenOsipov @SearsRosie @RYEbright

[Richard Y. Ebright, MD, PhD @RYEbright]

Daraxonrasib (aka Rasonque) now approved for pancreatic cancer!! An incredible advance that will bring so much benefit to patients. And it's just the beginning: many more major #KRAS advances to come soon, across many cancer types.

https://t.co/9STWGCtEgO

[Richard Y. Ebright, MD, PhD @RYEbright]

Last year, we reported that KRAS+PRMT5 is synergistic in MTAP-null PDAC (https://t.co/mIc6hkbMpL). Today, the first clinical data for a KRAS/PRMT5 combination was reported, with an incredible 92% ORR.

RAS inhibitors are the present, but combinations are the future!!
$TNGX $RVMD

[Richard Y. Ebright, MD, PhD @RYEbright]

Happy to have contributed to this new work from @KathleenMulvan4 and @TheSellersLab, showing that KRAS and PRMT5 inhibitors synergy, out now in Cancer Research. KRAS/PRMT5 combos ($RVMD/$TNGX) are now in clinical trials, and results couldn't come sooner!
https://t.co/mIc6hkbMpL

[Richard Y. Ebright, MD, PhD @RYEbright]

Absolutely incredible to see the massive benefit of RAS inhibition in pancreatic cancer patients, changing the field as I finish my training!! Led by one of my clinical mentors, Brian Wolpin, and received with standing ovation.

Also very cool to be cited in the discussion :)

[Adam Feuerstein ✡️ @adamfeuerstein]

Incredible #ASCO26 moment.

Dr. Brian Wolpin, presenter of the daraxonrasib study, received a standing ovation DURING his talk after he stated the survival benefit for PDAC patients. It was sustained. Cheering. I have never see anything like it in the middle of a talk. $RVMD

[Richard Y. Ebright, MD, PhD @RYEbright]

A new standard for PDAC. Daraxonrasib with 13.2m OS in 2L, and next-generation molecules in development. #RAS

Incredible to see this field changing as I finish training.

Congrats to $RVMD, @NextechInvest + @schroederthilo, and to all the patients!!!

https://t.co/QSwHNJKJte

[Richard Y. Ebright, MD, PhD @RYEbright]

Happy to have contributed to this new work from @KathleenMulvan4 and @TheSellersLab, showing that KRAS and PRMT5 inhibitors synergy, out now in Cancer Research. KRAS/PRMT5 combos ($RVMD/$TNGX) are now in clinical trials, and results couldn't come sooner!
https://t.co/mIc6hkbMpL

[Richard Y. Ebright, MD, PhD @RYEbright]

So many important, practice-changing presentations at #ASCO25, but the best part was seeing the work of my incredible @DanaFarber co-fellows 🌟🌟🌟
@SaraKCharMD @SWaliany @tess_omeara @AshleyOdai

[Kimmie Ng, MD, MPH @KimmieNgMD]

No doubt the best GI Onc division on the planet! So grateful to work with brilliant, kind, and visionary colleagues #ASCO25 @DanaFarber @DanaFarberNews @DFarberYoungCRC @ASCO

[Richard Y. Ebright, MD, PhD @RYEbright]

Disgusting.

[The Boston Globe @BostonGlobe]

The Trump administration has moved to terminate scores of research grants at Harvard University and its medical school, imperiling scores of research projects and potentially upending the futures of dozens of young scientists. https://t.co/PXz91lOI0v

[Richard Y. Ebright, MD, PhD @RYEbright]

@OscarTahuahua Great summary, thanks for highlighting the review!👌👌

[Richard Y. Ebright, MD, PhD @RYEbright]

@aparna1024 @MGHCancerCenter @bostonmarathon @colinjoyproject Have a great race Aparna!!

[Reid Huber @ReidHuber]

56 FDA/CDER novel drug approvals in 2023 (+51% from 2022)

Accelerated approval: 9
Orphan drug designations: 18
Fast track designation: 16
Priority review: 24
Breakthrough therapy: 9

[Richard Y. Ebright, MD, PhD @RYEbright]

Congrats to the next wave of @DanaFarber / @MGHCancerCenter fellows!! An incredible group coming from @mghmedres! @MattMeiz @DylanJMartini @ben_ouyang @SiennaDurbin

[Richard Y. Ebright, MD, PhD @RYEbright]

@psrajendran87 @mghmedres @DOM_UCLA @uclaCVfellows @gcfmd @kewatson @datsunian @shivkumarmd Congrats Pradeep!! They’re lucky to have you!

[Richard Y. Ebright, MD, PhD @RYEbright]

@SamWattrus @BCHStemCell @MGH_RI Congrats Sam! Well deserved!!

[Richard Y. Ebright, MD, PhD @RYEbright]

@_emmarosewest @Forbes @jykishi Congrats Emma! Excited to see it grow!